Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Clinical Chemistry 42: 809-812, 1996;
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by LeBar, W. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by LeBar, W. D.

Clinical Chemistry, Vol 42, 809-812, Copyright © 1996 by American Association for Clinical Chemistry

Keeping up with new technology: new approaches to diagnosis of Chlamydia infection

WD LeBar
Citation Clinical Laboratories-Providence Hospital, Southfield, MI 48075, USA.

Chlamydia trachomatis infections are among the most common sexually transmitted infections in the US today. One of the keys to the prevention of C. trachomatis infection rests on the ability to make this diagnosis on the basis of accurate laboratory testing. For many years the standard for diagnosis of C. trachomatis infections has been isolation in tissue culture. Numerous nonculture methods, including enzyme immunoassay, have been used as an alternative to cell culture. The performance characteristics of these tests have all been compared with a standard, cell culture, which at best will detect 90% of positive specimens. Nucleic acid amplification techniques, including PCR and ligase chain reaction, have been recently introduced. The advantage of these tests is their ability to detect 10-20% more positive specimens when compared with culture or confirmed nonculture methods performed with a single specimen. The sensitivity of amplified tests also allows us to test specimens from multiple sites (endocervix, urethra, urine), which expands our standard from an infected sample to detection of an infected patient. Tests based on amplified nucleic acid technology have greatly improved our ability to diagnose urogenital C. trachomatis infection. The use of an expanded standard will help us accurately define the true performance and clinical utility of nonculture Chlamydia diagnostic tests.


The following articles in journals at HighWire Press have cited this article:


Home page
J. Clin. Microbiol.Home page
A. J. McAdam
Discrepant Analysis: How Can We Test a Test?
J. Clin. Microbiol., June 1, 2000; 38(6): 2027 - 2029.
[Full Text]


Home page
Arch Pediatr Adolesc MedHome page
M. K. Oh, K. R. Smith, M. O'Cain, D. Kilmer, J. Johnson, and E. W. Hook III
Urine-Based Screening of Adolescents in Detention to Guide Treatment for Gonococcal and Chlamydial Infections: Translating Research Into Intervention
Arch Pediatr Adolesc Med, January 1, 1998; 152(1): 52 - 56.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1996 by the American Association for Clinical Chemistry.